Antibody Analytics is a specialist contract research organisation, supporting drug development companies who are creating biological-based therapies to treat a range of life-threatening human diseases, including cancer. Antibody Analytics has foundational expertise in the development of advanced medicines, such as monoclonal antibodies and latterly in more complex, investigational therapeutic modalities such as multi-specific antibodies, antibody-drug conjugates and engineered cell therapies, all of which have significant potential to become transformational, and even curative treatments for patients.
Antibody Analytics has diversified significantly since its inception in 2015 and has evolved the business from the characterisation of biosimilar (typically monoclonal antibody) products to becoming trusted advisers in the field of immuno-oncology pre-clinical drug development, which is now hailed as the fifth pillar of cancer treatment. Antibody Analytics has a global customer base and is recognised for its immersive, consultative approach to pre-clinical research and characterisation activities.
The staff at Antibody Analytics have a breadth of experience, ranging from bioanalytical experts, with decades of experience in bioassay design to academics with a focus on basic immunology to those who have worked in the drug development industry themselves. This provides Antibody Analytics with a comprehensive overview of the drug discovery process, affording them an awareness of the challenges facing the inventors of complex biologic therapeutic candidates.